Fast Five Quiz: Management of Chronic Kidney Disease Anemia

Pradeep Arora, MD


April 19, 2022

Despite clinical success, ESAs are generally administered when hemoglobin levels are < 10 g/dl owing to the risk for adverse effects. A 2009 study demonstrated that ESAs are associated with an increased risk for cardiovascular events, CKD progression, vascular access thrombosis, and overall mortality, particularly at higher doses.

Learn more about CKD anemia management.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.